FindTrial
Sign In

THE MAJOR FACTOR AFFECTING IOP SPIKES AFTER INTRAVITREAL RANIBIZUMAB INJECTION: VITREOUS REFLUX AND ITS AMOUNT

THE MAJOR FACTOR AFFECTING IOP SPIKES AFTER INTRAVITREAL RANIBIZUMAB INJECTION: VITREOUS REFLUX AND ITS AMOUNT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180327001
Enrollment
Unknown
Registered
2018-03-27
Start date
2017-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assess the effect of vitreous reflux and its amount on short&#45

Interventions

term intraocular pressure after intravitreal injection of ranibizumab
No Intervention Procedure/Surgery
Ranibizumab
Assess the effect of vitreous reflux and its amount on short&#45

Sponsors

Enes Uyar
Lead Sponsor
Fatih Ulas
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: baseline IOP < 25 mmHg&#44; without history of glaucoma or uveitis&#44; and without history of intraocular surgery except for uncomplicated cataract surgeries

Exclusion criteria

Exclusion criteria: Patients who had intravitreal treatment other than intravitreal ranibizumab and those having any ocular surface diseases interfering with contact IOP measurement

Design outcomes

Primary

MeasureTime frame
intraocular pressure Before&#44; Immediately after and 30 minute after intravitreal injection Handheld tonometer(Tonopen avia)—

Secondary

MeasureTime frame
Vitreous reflux immediately after intravitreal injection a ruler—

Countries

Turkey

Contacts

Public ContactEnes Uyar

Aksaray Training and Research Hospital

enuyar@gmail.com+905368592664

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026